Santiago Gisler,  —

Biotech company Saniona announced the formation of a scientific advisory board to supervise and guide the developmental program of Tesomet (tesofensine/metoprolol) for patients with Prader-Willi Syndrome (PWS). The company also extended its Phase 2a open-label study (NCT03149445), testing the safety and efficacy of the treatment, in the…

Millendo Therapeutics has launched a Phase 2b/3 clinical trial investigating the safety and efficacy of livoletide (AZP-531) in patients with Prader-Willi syndrome (PWS), the company announced. The rare genetic disease is characterized by hyperphagia (excessive eating) and obesity, caused by abnormal hormonal levels. Livoletide is designed to reduce…

The Data Safety Monitoring Board recommended the continuation of Soleno Therapeutics’ Phase 3 clinical trial evaluating the effects of diazoxide choline controlled release (DCCR) treatment in children and adults with Prader-Willi syndrome (PWS), the company announced. Hyperphagia (excessive eating) is a classic PWS symptom caused by hormonal or…

Wearable sensors to detect movement showed differences in motor abilities in children with Prader-Willi syndrome (PWS) and Down syndrome, compared with healthy children. Researchers say these sensors could be used to personalize patient therapy based on specific motor limitations. “Dynamic balance assessment during gait in children with Down and…

Impairments in behavioral and working memory tasks are seen in people with Prader-Willi syndrome (PWS) compared with healthy controls, a new study shows. The study, “Investigation of the relationship between electrodermal and behavioural responses to executive tasks in Prader-Willi syndrome: An event-related experiment,” was published in the journal…